<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01222962</url>
  </required_header>
  <id_info>
    <org_study_id>ST3073/ST3074-DM09-008</org_study_id>
    <nct_id>NCT01222962</nct_id>
  </id_info>
  <brief_title>Food Interaction Study on the Pharmacokinetics of Eurartesim™ (DHA and PQP)in Healthy Male Adult Volunteers</brief_title>
  <official_title>Study of the Effect of Food on the Pharmacokinetics of DHA and PQP After Single Oral Administration of Eurartesim™ in Healthy Male Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>sigma-tau i.f.r. S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CPR Pharma Services Pty Ltd, Australia</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>sigma-tau i.f.r. S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was designed to assess the effect of food on the extent and rate of absorption of
      Dihydroartemisinin (DHA) and Piperaquine Phosphate (PQP) administered as a fixed dose
      combination (Eurartesim™).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tmax, Cmax, AUC0-last, AUC0-24 [PQ], and AUC0-inf, λz, t1/2, Cl/F, Vz/F [DHA].</measure>
    <time_frame>from the day of study drug administration, till Day 7 follow-up</time_frame>
    <description>Blood samples for determination of plasma DHA were collected at the following times: At pre-dose Day 0 and then at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, and 12 hours post-dose.
Blood samples for determination of plasma PQ were collected at the following times: At pre-dose Day 0 and then at 1, 2, 3, 4, 5, 6, 8, and 12 hours post-dose; on Day 1, 2, 3, 4, 5 and 7.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Treatment Emergent Adverse Events</measure>
    <time_frame>Day 0 and till Day 30 follow-up</time_frame>
    <description>Number of TEAEs and number of Subjects experiencing Adverse Events during all the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematology and blood chemistry changes respect to baseline values</measure>
    <time_frame>Day 0, day 2, day 30</time_frame>
    <description>Abnormalities in hematology (Haemoglobin, Hematocrit,RBC count, White cell count and differential count, Platelets) and clinical chemistry (Protein, Sodium, Potassium, Chloride ,Total Bilirubin, Conjugated Bilirubin, Alanine Aminotransferase, Aspartate Aminotransferase, Total Cholesterol, Glucose, Bicarbonate, Urea, Urate, Lactate Dehydrogenase, Albumin, Globulins, Triglycerides, Creatinine, Alkaline Phosphatase, Gamma glutamyltransferase, Total Calcium, Phosphate, C-reactive protein) will be recorded the day of the last study drug intake and after 30 days from the start of the drug treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTc interval prolongation</measure>
    <time_frame>Day 0, day 2, day 30</time_frame>
    <description>ECG recordings will be obtained at baseline, after the last drug intake and 30 days follow-up to investigate changes in ECG parameters, and specifically QTc interval changes respect to baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Malaria, Falciparum</condition>
  <arm_group>
    <arm_group_label>fed treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18 healthy volunteers administered with a single dose of Eurartesim</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fasted Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18 healthy volunteers treated with a single dose of Eurartesim</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eurartesim</intervention_name>
    <description>Tablet containing 40 mg of Dihydroartemisinin (DHA) and 320 mg of Piperaquine phosphate (PQP). 4 Tablets a Day for body weight above 75 kg.</description>
    <arm_group_label>fed treatment</arm_group_label>
    <arm_group_label>Fasted Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasian healthy males aged between 18 and 50 years(inclusive).

          -  Body Mass Index (BMI) between 19.0 kg/m2 and 27.0 kg/m2 inclusive, with a minimum body
             weight of 75 kg.

          -  Agreed to use two approved methods of contraception from Screening and until 90 days
             after administration of the study drug

          -  Had given written informed consent to participate in this study in accordance with
             local regulations.

        Exclusion Criteria:

          -  Had received or was anticipated to receive a prescription medication within 14 days
             prior to the start of dosing or an over-the-counter medicine 48 hours prior to the
             start of dosing.

          -  Abnormal laboratory test results deemed clinically significant by the Medical Officer.

          -  Positive urine drug test (e.g. opiates and cannabinoids) or alcohol breath test.

          -  History of significant drug allergies or significant allergic reaction.

          -  Receipt of blood or blood products, or loss or donation of 450 mL or more of blood
             within 90 days before the first dose administration.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CMAX, a division of IDT Australia Limited</name>
      <address>
        <city>Adelaide</city>
        <zip>SA 5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2010</study_first_submitted>
  <study_first_submitted_qc>October 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2010</study_first_posted>
  <last_update_submitted>October 14, 2010</last_update_submitted>
  <last_update_submitted_qc>October 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Giovanni Valentini, MD</name_title>
    <organization>Medical Department, R&amp;D Division, Sigma-Tau ifr SpA</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

